Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Down 3.6%

Centessa Pharmaceuticals plc (NASDAQ:CNTAGet Free Report)’s share price traded down 3.6% on Monday . The stock traded as low as $10.56 and last traded at $10.89. 38,505 shares traded hands during trading, a decline of 90% from the average session volume of 400,675 shares. The stock had previously closed at $11.30.

Wall Street Analyst Weigh In

Separately, BMO Capital Markets reaffirmed an “outperform” rating and set a $15.00 price objective on shares of Centessa Pharmaceuticals in a research report on Monday. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Centessa Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Read Our Latest Stock Analysis on CNTA

Centessa Pharmaceuticals Trading Up 2.3 %

The company has a debt-to-equity ratio of 0.29, a current ratio of 9.51 and a quick ratio of 9.51. The business has a 50-day moving average price of $10.21 and a 200 day moving average price of $8.01.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, SVP Harris Rotman sold 4,267 shares of the stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $8.10, for a total transaction of $34,562.70. Following the sale, the senior vice president now directly owns 62,625 shares in the company, valued at approximately $507,262.50. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 51,160 shares of the stock in a transaction on Monday, March 25th. The stock was sold at an average price of $11.88, for a total transaction of $607,780.80. Following the sale, the insider now directly owns 71,525 shares in the company, valued at approximately $849,717. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Harris Rotman sold 4,267 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $8.10, for a total value of $34,562.70. Following the sale, the senior vice president now owns 62,625 shares in the company, valued at $507,262.50. The disclosure for this sale can be found here. Insiders own 11.54% of the company’s stock.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of CNTA. Barclays PLC bought a new position in shares of Centessa Pharmaceuticals during the 1st quarter valued at $25,000. JPMorgan Chase & Co. lifted its holdings in shares of Centessa Pharmaceuticals by 275.9% during the 4th quarter. JPMorgan Chase & Co. now owns 12,747 shares of the company’s stock valued at $39,000 after buying an additional 9,356 shares during the period. Quarry LP bought a new position in shares of Centessa Pharmaceuticals during the 4th quarter valued at $48,000. Susquehanna International Group LLP bought a new position in shares of Centessa Pharmaceuticals during the 1st quarter valued at $49,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Centessa Pharmaceuticals by 371.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,394 shares of the company’s stock valued at $51,000 after buying an additional 5,037 shares during the period. 82.01% of the stock is owned by institutional investors.

About Centessa Pharmaceuticals

(Get Free Report)

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.

See Also

Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.